Interesting in the Edison Group Video presentation that SI mentions 'with our partner' in relation to COVID-19 ARDS .... is this the NIH who is looking to fund another phase 3 COVID-19 ARDS trial due to the deteriorating situation in the USA or a new pharma group altogether wanting to pursue Remestemcel-L as a possible treatment for COVID-19 ARDS ?
Sadly, the situation in the USA is not improving according to the NYT who provide free daily updates on their home page
https://www.nytimes.com/
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-109
-
- There are more pages in this discussion • 797 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
-0.005(0.42%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.18 | $313.3K | 265.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21092 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 4650 | 1 |
View Market Depth
| Last trade - 10.06am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |